---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-046572"
form_type: "8-K"
ticker: "IBO"
cik: "0001834105"
company_name: "IMPACT BIOMEDICAL INC."
filed_at: "2026-10-09T20:58:52+00:00"
generated_at: "2026-10-12T15:02:22.752926+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Impact BioMedical completes 1-for-12.62 reverse stock split effective September 23, 2026

## Summary
- Reverse split ratio is 1-for-12.62, effective 12:01 A.M. EST on September 23, 2026; IBO began trading split-adjusted on NYSE American.
- Outstanding shares fell from about 107.8 million to about 8.6 million; authorized shares, $0.001 par value, and voting rights were unchanged.
- New CUSIP is 45259L304; Equiniti Transfer & Trust Company is exchange agent; no fractional shares were issued, with fractional holders receiving one full share.
- Board approved reverse split on November 24, 2025, and majority stockholders approved it on December 30, 2025, with CEO given discretion on ratio.
- Nevada Secretary of State clerical error delayed the file-stamped Amendment until October 6, 2026, after effectiveness on September 23, 2026.

## SEC filing metadata
- accession: 0001493152-26-046572
- form_type: 8-K
- ticker: IBO
- cik: 0001834105
- company_name: IMPACT BIOMEDICAL INC.
- filed_at: 2026-10-09T20:58:52+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834105/000149315226046572/0001493152-26-046572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834105/000149315226046572/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-046572
- JSON: https://secwatch.observer/filing/0001493152-26-046572.json
- Plain text: https://secwatch.observer/filing/0001493152-26-046572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.